Home » Stocks » KMPH

KemPharm, Inc. (KMPH)

Stock Price: $10.31 USD -0.68 (-6.19%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $10.44 +0.13 (1.26%) Jul 29, 7:25 PM
Market Cap 372.50M
Revenue (ttm) 23.32M
Net Income (ttm) -54.75M
Shares Out 19.15M
EPS (ttm) -6.83
PE Ratio n/a
Forward PE 28.90
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $10.31
Previous Close $10.99
Change ($) -0.68
Change (%) -6.19%
Day's Open 11.09
Day's Range 10.26 - 11.25
Day's Volume 739,397
52-Week Range 5.08 - 18.15

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CELEBRATION, Fla., July 21, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced t...

1 week ago - GlobeNewsWire

Investors reacted negatively to the company's warrant exchange.

1 month ago - The Motley Fool

CELEBRATION, Fla., June 18, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced i...

1 month ago - GlobeNewsWire

CELEBRATION, Fla., June 16, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced t...

1 month ago - GlobeNewsWire

KemPharm Inc. (NASDAQ:KMPH) shares moved higher Thursday after it was announced the company is being added to the Russell 3000 and Russell 2000 indexes based on the index provider's annual reconstitutio...

1 month ago - Benzinga

CELEBRATION, Fla., June 09, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today i...

1 month ago - GlobeNewsWire

CELEBRATION, Fla., June 03, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced t...

1 month ago - GlobeNewsWire

SDX is KemPharm's proprietary prodrug of d-methylphenidate (d-MPH) and the primary active pharmaceutical ingredient (API) in AZSTARYS™

2 months ago - GlobeNewsWire

Corporate and Regulatory Highlights

2 months ago - GlobeNewsWire

KP879, KemPharm's Lead Product Candidate Based on SDX and Intended for the Treatment of Stimulant Use Disorder (SUD), Could Be Schedule IV, If Approved by the FDA

2 months ago - GlobeNewsWire

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, May 13, 2021, 4:30 p.m. ET

2 months ago - GlobeNewsWire

Eligible to Receive Additional Near-Term $10 Million Milestone Payment Following DEA Scheduling of SDX

3 months ago - GlobeNewsWire

KemPharm Inc (NASDAQ: KMPH) has amended the collaboration and license agreement with Gurnet Point Capital (GPC), a private investment firm. The agreement provides for an exclusive worldwide license to d...

3 months ago - Benzinga

Amendment Increases Total Potential Regulatory and Sales Milestone Payments to $590 Million, and Adds a New Top-Level Tier for Royalties on U.S. Net Sales

3 months ago - GlobeNewsWire

KemPharm has a new ADHD drug, but after a recent short-squeeze KMPH stock is likely to fall without further financing. The post KemPharm Stock Is Too Good to Be True After Its Recent Run-up appeared fir...

4 months ago - InvestorPlace

Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

KemPharm (KMPH) stock is gaining interest on Twitter (TWTR) from retail traders that think it might be the next GameStop (GME). The post KMPH Stock: Why Twitter Thinks KemPharm Is the New GME Short Sque...

Other stocks mentioned: TWTR
4 months ago - InvestorPlace

Corporate and Regulatory Highlights:

4 months ago - GlobeNewsWire

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, March 11, 2021, 4:30 p.m. ET

4 months ago - GlobeNewsWire

CELEBRATION, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced ...

4 months ago - GlobeNewsWire

KemPharma (KMPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

4 months ago - Zacks Investment Research

What a day. We saw the morning start with a new iteration of the Reddit stocks rally, and the afternoon close with new fears about digital ad companies.

Other stocks mentioned: FVRR, SOS
4 months ago - InvestorPlace

The FDA approves KemPharm's (KMPH) NDA for Azstarys for the treatment of attention deficit hyperactivity disorder in patients aged six years and older. Shares rise.

4 months ago - Zacks Investment Research

Ovid Therapeutics Inc. (NASDAQ: OVID), KemPharm Inc (NASDAQ: KMPH), Aquestive Therapeutics Inc (NASDAQ: AQST) and Sorrento Therapeutics, Inc. (NASDAQ: SRNE) were among the health care gainers in Wednesd...

Other stocks mentioned: SRNE
4 months ago - Benzinga

KemPharm's prodrug development platform got a huge boost from the FDA's new drug application nod for an ADHD treatment. The post KMPH Stock: The Big News That Has KemPharm Soaring Today appeared first o...

4 months ago - InvestorPlace

The FDA has approved KemPharm Inc's (NASDAQ: KMPH) market application for Azstarys (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (AD...

4 months ago - Benzinga

Conference Call and Live Audio Webcast Scheduled for Tomorrow, Wednesday, March 3, at 8:30 a.m. ET

4 months ago - GlobeNewsWire

Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

Financial Restructuring and Nasdaq Re-Listing Process Completed

6 months ago - GlobeNewsWire

Combination of Oral and Poster Presentations Scheduled for January 15, 2021

6 months ago - GlobeNewsWire

CELEBRATION, Fla., Jan. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced t...

6 months ago - GlobeNewsWire

Common stock will begin trading on The Nasdaq Capital Market under the ticker symbol “KMPH” today, January 8, 2021

6 months ago - GlobeNewsWire

CELEBRATION, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced th...

7 months ago - GlobeNewsWire

CELEBRATION, Fla., Dec. 22, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced it...

7 months ago - GlobeNewsWire

CELEBRATION, Fla., Dec. 02, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced th...

7 months ago - GlobeNewsWire

Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET

7 months ago - GlobeNewsWire

IND for KP879 Expected to be Filed Before Year-End 2020; New Prodrug Candidate Added to Pipeline , Targeting Rare CNS Disease , Idiopathic Hypersomnia (IH)

8 months ago - GlobeNewsWire

Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET

8 months ago - GlobeNewsWire

KemPharm, Inc. (KMPH) CEO Travis Mickle on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4 : 3 0 p.m. ET

9 months ago - GlobeNewsWire

Special Meeting of Stockholders Rescheduled to Tues day , Nov 17, 2020, 8:00 a.m. ET

9 months ago - GlobeNewsWire

CELEBRATION, Fla., Oct. 22, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced th...

9 months ago - GlobeNewsWire

New agreement provides additional revenue potentially through Q1 2022

9 months ago - GlobeNewsWire

4 Small Drug Stocks to Look Out For Amid Coronavirus Uncertainty

Other stocks mentioned: ALDX, NERV, SAVA
9 months ago - Zacks Investment Research

CELEBRATION, Fla., Sept. 25, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (KemPharm, or the Company) (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietar...

10 months ago - GlobeNewsWire

Pilot program initially launching in Alabama aligns APADAZ with Sure Med’s Care Continuity Program® to collect data and create a more informed opioid prescribing environment

10 months ago - GlobeNewsWire

Presentations to Highlight Corporate, Regulatory and Pipeline Advancements Presentations to Highlight Corporate, Regulatory and Pipeline Advancements

10 months ago - GlobeNewsWire

CELEBRATION, Fla., Aug. 14, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced ...

11 months ago - GlobeNewsWire

KemPharm, Inc. (KMPH) CEO Travis Mickle on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, August 12, 2020, 4:30 p.m. ET Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesd...

11 months ago - GlobeNewsWire

About KMPH

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CN... [Read more...]

Industry
Biotechnology
IPO Date
Apr 16, 2015
CEO
Travis Mickle
Employees
22
Stock Exchange
NASDAQ
Ticker Symbol
KMPH
Full Company Profile

Financial Performance

In 2020, KemPharm's revenue was $13.29 million, an increase of 3.50% compared to the previous year's $12.84 million. Losses were -$12.76 million, -47.97% less than in 2019.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for KemPharm is 19.00, which is an increase of 84.29% from the latest price.

Price Target
$19.00
(84.29% upside)